Waylivra approved for use in the EU.
We are the leader in discovering and developing RNA-targeted therapeutics. Our efficient, broadly applicable drug discovery platform, called antisense technology, can treat illnesses where no other therapeutic approaches have proven effective or ever existed.
We look to patients and their loved ones to help us better understand what it means to live with disease, so we can focus our efforts where we believe we can make the most meaningful contribution to improve lives.
Our drug discovery platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases.
From the moment of our founding, we knew we could transform the biopharmaceutical industry. We had the people, the science and the unwavering commitment to bring about a new approach to drug discovery and development that would deliver innovative treatments to patients where no others had proven effective or ever existed.
If you have this same commitment to be a force for life and feel that Ionis is right for you, we want to hear from you.
